Sphere Fluidics
Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems to enable leading edge research and accelerate biotherapeutic discovery and development. The Company’s picodroplet incubation technology enables ultra-sensitive, rapid miniaturized assays of target proteins secreted from tens of millions of individual cells. Sphere Fluidics’ Cyto-Mine® System integrates isolation, selective screening, sorting, imaging, and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Sphere Fluidics is located in Babraham Research Campus and Granta Park in Cambridgeshire (UK).
Sector
Biopharmaceuticals
Strategy
Crossover
Status
Active
Website
spherefluidics.com
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.